Information Provided By:
Fly News Breaks for December 26, 2019
Dec 26, 2019 | 06:43 EDT
The economics in Sarepta Therapeutics' (SRPT) outside the U.S. Roche (RHHBY) partnership look attractive, Citi analyst Joel Beatty tells investors in a research note. The deal gives Sarepta additional non-dilutive cash, developmental cost sharing for its Duchenne muscular dystrophy gene therapy program, and "a level of validation that manufacturing is headed in the right direction," according to Beatty. The analyst keeps a Buy rating on Sarepta shares with a $177 price target.
News For SRPT;RHHBY From the Last 2 Days
There are no results for your query SRPT;RHHBY